scholarly journals Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study: Erratum

2015 ◽  
Vol 6 (2) ◽  
pp. 122
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Adverse Drug Reactions ◽  
Myeloid Leukemia ◽  
Surveillance Study ◽  
Single Center ◽  
Drug Reactions

scholarly journals Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study

2015 ◽  
Vol 6 (1) ◽  
pp. 30 ◽  
Author(s):  
Jose Francis ◽  
Muthiah Palaniappan ◽  
SureshChandra Pradhan ◽  
Adithan Chandrasekaran ◽  
Biswajit Dubashi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Adverse Drug Reactions ◽  
Myeloid Leukemia ◽  
Surveillance Study ◽  
Single Center ◽  
Drug Reactions

scholarly journals Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience

2021 ◽  
Vol 10 (4) ◽  
pp. 706
Author(s):  
José V. Pérez-Moreiras ◽  
María Varela-Agra ◽  
M. Consuelo Prada-Sánchez ◽  
Guillermo Prada-Ramallal
Keyword(s):  
Adverse Drug Reactions ◽  
Disease Recurrence ◽  
Clinical Activity ◽  
Eyelid Retraction ◽  
Single Center ◽  
Drug Reactions ◽  
Steroid Resistant ◽  
Single Center Experience ◽  
Graves Orbitopathy ◽  
The Absolute

This study aimed to assess the effectiveness and safety of tocilizumab use for the treatment of active steroid-resistant Graves’ orbitopathy (GO). A retrospective longitudinal study was conducted by reviewing the medical records at a single center between November 2009 and December 2018. A total of 114 patients with steroid-resistant Graves’ orbitopathy were examined and treated with tocilizumab, of which 54 adults met the inclusion criteria. No concomitant medication for the treatment of orbitopathy was used. The main primary outcomes included changes from baseline in the Clinical Activity Score (CAS) and thyrotropin receptor antibody (TRAb) levels throughout therapy with tocilizumab. The absolute responses to treatment were defined as the achievement of CAS ≤ 1 and TRAb ≤ 10 U/L. A composite ophthalmic score including CAS, proptosis, eyelid retraction, and diplopia was used to evaluate individual improvement in GO. Adverse drug reactions were also assessed. Analysis of the patient’s CAS and TRAb levels showed meaningful reductions during tocilizumab treatment. Differences between values at baseline and subsequent time points were statistically significant (p < 0.001 for all comparisons). The absolute CAS response (CAS = 0 or 1) was achieved in 74% (37/50) of patients after the fourth dose of tocilizumab (at week 16), with a TRAb response being achieved in 55% (23/42) of patients. The relative CAS response (reduction ≥ 2 points) was achieved in 90.9% of patients (40/44) after the first dose of tocilizumab (at week 4). Measurements of proptosis (reduction ≥ 2 mm in 78% of patients, 42/54) and eyelid retraction (reduction ≥ 2 mm in 75%, 33/44), and the prevalence of diplopia (improvement in 68%, 19/28) were significantly reduced after the last dose of tocilizumab (p < 0.001 for all comparisons). GO improved in 98% (53/54) of patients when at least two criteria of the composite evaluation were required. Four patients exhibited disease recurrence, defined as an increase in CAS of ≥2 points in the six months following the date of inactivation. Most adverse drug reactions were mild or moderate in severity. In conclusion, our data suggest that a course of at least 4 months (one monthly dose) of tocilizumab therapy provides a significant benefit to patients with active moderate-to-severe steroid-resistant GO.

Pediatric chronic myeloid leukemia: A single-center experience

2020 ◽  
Vol 16 (1) ◽  
pp. 110
Author(s):  
Irappa Madabhavi ◽  
Apurva Patel ◽  
Gaurang Modi ◽  
Asha Anand ◽  
Harsha Panchal ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Single Center ◽  
Single Center Experience

Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India

2020 ◽  
Vol 20 (7) ◽  
pp. e437-e444
Author(s):  
Shuvadeep Ganguly ◽  
Deepam Pushpam ◽  
Agrima Mian ◽  
Anita Chopra ◽  
Ritu Gupta ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Real World ◽  
Myeloid Leukemia ◽  
Chronic Phase ◽  
Single Center ◽  
Single Center Experience

scholarly journals Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience

1997 ◽  
Vol 20 (12) ◽  
pp. 1057-1062 ◽  
Author(s):  
T Lamparelli ◽  
MT Van Lint ◽  
F Gualandi ◽  
D Occhini ◽  
M Barbanti ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Chronic Myeloid Leukemia ◽  
Marrow Transplantation ◽  
Myeloid Leukemia ◽  
Single Center ◽  
Single Center Experience

scholarly journals Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience

1999 ◽  
Vol 24 (3) ◽  
pp. 265-270 ◽  
Author(s):  
A Pigneux ◽  
C Faberes ◽  
JM Boiron ◽  
FX Mahon ◽  
P Cony-Makhoul ◽  
...  
Keyword(s):  
Stem Cell ◽  
Chronic Myeloid Leukemia ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Myeloid Leukemia ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document